S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
AQST · Aquestive Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Aquestive Therapeutics Inc (AQST)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$4.08
+0.02
(+0.49%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$4.08
$4.03
$4.18
52-WEEK RANGE
$4.08
$2.93
$7.55
What's happening
- AQST is up 0.49% today, trading at $4.08. — Live quote
- Volume today (89,173) is well below its 3-month average of 2,603,050. (Finnhub fundamentals)
- Reports earnings on 2026-11-09 (after market close), 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.08 actual vs. $-0.11 estimated (+24.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (15 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
AQST
-40.71%
vs S&P 500
-53.11%
1-YEAR RETURN
AQST
-45.90%
vs S&P 500
-61.27%
6-MONTH RETURN
AQST
-9.67%
3-MONTH RETURN
AQST
-2.92%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.08
Est. $-0.11
BEAT +24.1%
2026-04-26 (Q1 2026)
$-0.07
Est. $-0.14
BEAT +50.0%
2026-01-26 (Q4 2025)
$-0.15
Est. $-0.14
MISS -10.9%
2025-10-26 (Q3 2025)
$-0.14
Est. $-0.14
MISS -3.6%
Valuation Measures & Ratios
Enterprise Value4$552.5M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)9.43
Price / Book715.59
EV4 / Revenue10.21
EV4 / EBITDA—
Profit Margin-144.63%
Operating Margin-119.12%
Return on Equity (ROE8)-21.76%
Return on Assets (ROA9)-52.39%
Avg Volume (3M)2,603,050
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $528.4M | $477.7M | $615.6M | $320.3M | $277.1M |
| P/E | -8.82 | -7.96 | -9.71 | -6.31 | -5.54 |
| Price/Sales | 10.35 | 10.39 | 13.66 | 6.12 | 5.09 |
| Price/Book | -9.34 | -14.03 | -149.83 | -4.41 | -4.55 |
| EV/Revenue | 9.49 | 8.96 | 11.79 | 5.82 | 4.66 |
| ROE | 105.88% | 176.13% | 1543.76% | 69.89% | 82.08% |
| ROA | -45.35% | -42.50% | -38.78% | -54.14% | -48.92% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short28,748,212
Change from Prior Settlement+5.84%
% of Float—
Days to Cover (Short Ratio)13.06
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 38.1% on the provider's reported measure. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-19; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -144.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -45.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on AQST
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.8M | $14.4M | $12.8M | $10.0M | $8.7M | $13.5M | $20.1M | $12.1M |
| Operating income | -$8.2M | -$4.2M | -$11.5M | -$11.4M | -$19.4M | -$8.3M | $55.0K | -$9.0M |
| Net income | -$22.9M | -$8.1M | -$15.4M | -$13.5M | -$22.9M | -$11.5M | -$2.7M | -$12.8M |
| EPS (diluted) | $-0.18 | $-0.07 | $-0.14 | $-0.14 | $-0.24 | $-0.13 | $-0.03 | $-0.17 |
| EPS (basic) | $-0.18 | $-0.07 | $-0.14 | $-0.14 | $-0.24 | $-0.13 | $-0.03 | $-0.17 |
| Operating margin | -$60 | -$29 | -$90 | -$114 | -$222 | -$61 | $0 | -$74 |
| Net margin | -$165 | -$56 | -$121 | -$135 | -$263 | -$85 | -$14 | -$106 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $132.1M | $141.1M | $160.4M | $163.6M | $93.7M | $102.2M | $101.4M | $110.0M |
| Total liabilities | $188.7M | $175.2M | $194.1M | $167.7M | $166.3M | $163.2M | $161.6M | $155.4M |
| Stockholders' equity | -$56.6M | -$34.1M | -$33.7M | -$4.1M | -$72.6M | -$60.9M | -$60.2M | -$45.4M |
| Total current assets | $118.5M | $130.2M | $149.3M | $151.7M | $81.7M | $89.2M | $88.2M | $96.6M |
| Total current liabilities | $16.5M | $31.8M | $47.6M | $25.6M | $23.2M | $18.3M | $18.9M | $15.2M |
| Cash & equivalents | $98.5M | $110.7M | $121.2M | $129.1M | $60.5M | $68.7M | $71.5M | $77.9M |
| Accounts receivable | $9.3M | $6.9M | $17.8M | — | — | — | $7.3M | — |
| Inventory | $7.4M | $8.1M | $6.2M | $7.9M | $8.1M | $7.2M | $6.0M | $7.0M |
| Property, plant & equipment | $4.0M | $3.8M | $3.9M | $3.9M | $3.9M | $3.8M | $3.8M | $3.8M |
| Intangible assets | — | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Other non-current assets | $1.7M | $2.6M | $2.6M | $3.2M | $3.2M | $4.2M | $4.2M | $4.2M |
| Accounts payable | $9.0M | $11.9M | $29.9M | $10.9M | $12.0M | $12.3M | $10.3M | $7.6M |
| Accrued liabilities | $4.5M | $3.4M | $5.0M | $5.1M | $5.0M | $3.3M | $5.9M | $5.0M |
| Deferred revenue (current) | $1.1M | $1.1M | $1.1M | $1.1M | $1.1M | $1.0M | $1.0M | $1.0M |
| Long-term debt | $55.0M | $45.0M | $45.0M | $45.0M | $45.0M | $45.0M | $45.0M | $45.0M |
| Other non-current liabilities | $6.2M | $6.1M | $7.3M | $2.1M | $2.1M | $2.2M | $2.4M | $2.0M |
| Common stock & paid-in capital | $126.0K | $124.0K | $122.0K | $121.0K | $99.0K | $99.0K | $91.0K | $91.0K |
| Retained earnings | -$477.9M | -$455.1M | -$447.0M | -$415.1M | -$399.7M | -$386.1M | -$363.2M | -$346.2M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.4M | -$14.8M | -$8.5M | -$12.6M | -$7.9M | -$23.4M | -$6.5M | -$11.9M |
| Investing cash flow | -$212.0K | -$52.0K | -$85.0K | -$235.0K | -$107.0K | -$135.0K | -$15.0K | -$80.0K |
| Financing cash flow | -$2.6M | $4.4M | $660.0K | $81.4M | -$100.0K | $20.6M | $157.0K | -$17.0K |
| Free cash flow | -$9.7M | -$14.9M | -$8.6M | -$12.9M | -$8.0M | -$23.5M | -$6.5M | -$12.0M |
| Capital expenditures | $212.0K | $52.0K | $85.0K | $235.0K | $107.0K | $135.0K | $15.0K | $80.0K |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $2.9M | $2.3M | $1.4M | $2.8M | $1.9M | $1.6M | $2.4M | $1.6M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | — | — | — | — | — | — | — | — |
| Change in inventory | -$706.0K | $1.9M | -$1.7M | -$241.0K | $927.0K | $1.2M | -$977.0K | $55.0K |
| Change in accounts payable | -$3.4M | -$18.0M | $19.2M | -$1.3M | -$323.0K | $1.9M | $2.6M | $1.9M |
| Debt issued | $54.3M | — | — | — | $0 | — | — | — |
| Tax withholding on stock comp | $3.2M | $329.0K | $18.0K | $70.0K | $19.0K | $703.0K | $1.0K | $202.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M | $50.8M |
| Operating income | -$71.1M | -$30.8M | -$15.1M | -$42.1M | -$34.7M |
| Net income | -$83.8M | -$44.1M | -$7.9M | -$54.4M | -$70.5M |
| EPS (diluted) | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 |
| EPS (basic) | $-0.78 | $-0.51 | $-0.13 | $-1.12 | $-1.85 |
| Operating margin | -$160 | -$53 | -$30 | -$88 | -$68 |
| Net margin | -$188 | -$77 | -$16 | -$114 | -$139 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $160.4M | $101.4M | $57.4M | $57.1M | $62.0M |
| Total liabilities | $194.1M | $161.6M | $163.9M | $175.6M | $144.1M |
| Stockholders' equity | -$33.7M | -$60.2M | -$106.5M | -$118.6M | -$82.1M |
| Total current assets | $149.3M | $88.2M | $41.0M | $39.9M | $47.3M |
| Total current liabilities | $47.6M | $18.9M | $18.3M | $39.5M | $22.0M |
| Cash & equivalents | — | — | — | — | — |
| Accounts receivable | $17.8M | $7.3M | $8.5M | — | — |
| Inventory | $6.2M | $6.0M | $6.8M | $5.8M | $4.0M |
| Property, plant & equipment | $3.9M | $3.8M | $4.2M | $4.1M | $5.1M |
| Intangible assets | $0 | $0 | $1.3M | $1.4M | $51.0K |
| Other non-current assets | $2.6M | $4.2M | $5.4M | $6.5M | $6.9M |
| Accounts payable | $29.9M | $10.3M | $8.9M | $9.9M | $8.3M |
| Accrued liabilities | $5.0M | $5.9M | $6.5M | $8.0M | $8.7M |
| Deferred revenue (current) | $1.1M | $1.0M | $1.6M | $1.5M | $765.0K |
| Long-term debt | $45.0M | $45.0M | $45.0M | — | — |
| Other non-current liabilities | $7.3M | $2.4M | $2.0M | $2.0M | $2.5M |
| Common stock & paid-in capital | $122.0K | $91.0K | $69.0K | $55.0K | $41.0K |
| Retained earnings | -$447.0M | -$363.2M | -$319.1M | -$311.2M | -$256.8M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$52.4M | -$35.8M | -$6.4M | -$9.8M | -$33.0M |
| Investing cash flow | -$562.0K | -$159.0K | -$995.0K | -$2.5M | -$913.0K |
| Financing cash flow | $102.6M | $83.6M | $4.0M | $11.6M | $30.1M |
| Free cash flow | -$53.0M | -$35.9M | -$7.4M | -$10.8M | -$33.9M |
| Capital expenditures | $562.0K | $159.0K | $995.0K | $1.0M | $913.0K |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $7.6M | $7.1M | $2.7M | $4.4M | $6.8M |
| Deferred income taxes | $0 | $0 | $0 | $0 | — |
| Change in inventory | $126.0K | -$725.0K | $989.0K | $1.7M | $1.6M |
| Change in accounts payable | $19.5M | $2.8M | -$1.0M | $1.6M | $1.2M |
| Tax withholding on stock comp | $810.0K | $1.1M | $11.0K | $3.0K | $14.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding AQST as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers49.2%
Shares Outstanding125,511,648
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Bratton Capital Management, L.P. | 9,810,958 | $40.8M | 7.82% | +0.0% | 2026-08-11 |
| BlackRock, Inc. | 8,069,373 | $33.6M | 6.43% | +7.5% | 2026-08-07 |
| RTW INVESTMENTS, LP | 7,426,471 | $30.9M | 5.92% | +0.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4,584,533 | $19.1M | 3.65% | +0.0% | 2026-06-30 |
| Federated Hermes, Inc. | 3,112,561 | $12.9M | 2.48% | +5.9% | 2026-08-12 |
| State Street Corp | 2,928,020 | $12.2M | 2.33% | +15.0% | 2026-08-07 |
| GEODE CAPITAL MANAGEMENT, LLC | 2,622,888 | $10.9M | 2.09% | +8.9% | 2026-08-12 |
| Samsara BioCapital, LLC | 2,500,000 | $10.4M | 1.99% | +0.0% | 2026-08-14 |
| Bank Of America Corp /De/ | 1,668,423 | $6.9M | 1.33% | -30.6% | 2026-08-14 |
| Sio Capital Management, LLC | 1,486,175 | $6.2M | 1.18% | -22.7% | 2026-07-15 |
| Propel Bio Management, LLC | 1,442,397 | $6.0M | 1.15% | +102.9% | 2026-08-13 |
| WASATCH ADVISORS LP | 1,385,843 | $5.8M | 1.10% | +57.8% | 2026-07-09 |
| TWO SIGMA INVESTMENTS, LP | 1,281,227 | $5.3M | 1.02% | +12.4% | 2026-08-07 |
| Nuveen, LLC | 1,215,225 | $5.1M | 0.97% | +379.4% | 2026-08-11 |
| Janney Montgomery Scott LLC | 1,106,160 | $4.6K | 0.88% | +1.6% | 2026-08-05 |
| Wells Fargo & Company/Mn | 1,089,037 | $4.5M | 0.87% | +5.3% | 2026-08-14 |
| COMMONWEALTH EQUITY SERVICES, LLC | 1,046,175 | $4.4M | 0.83% | -3.4% | 2026-07-29 |
| Barclays Plc | 996,665 | $4.1M | 0.79% | +24.7% | 2026-08-14 |
| Blue Owl Capital Holdings LP | 942,932 | $3.9M | 0.75% | -30.0% | 2026-08-11 |
| Northern Trust Corp | 831,151 | $3.5M | 0.66% | +13.5% | 2026-08-12 |
| BNP PARIBAS FINANCIAL MARKETS | 794,688 | $3.3M | 0.63% | -1.8% | 2026-08-10 |
| BALYASNY ASSET MANAGEMENT L.P. | 744,536 | $3.1M | 0.59% | -74.3% | 2026-08-13 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 734,245 | $3.1M | 0.59% | +0.0% | 2026-06-30 |
| Morgan Stanley | 658,617 | $2.7M | 0.52% | -58.6% | 2026-08-11 |
| VANGUARD FIDUCIARY TRUST CO | 651,211 | $2.7M | 0.52% | +0.0% | 2026-06-30 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-05-05 to 2026-10-15
Recent transactions
- Insiders have net sold 167,007 shares over the last 182 days, across 0 purchases and 9 sales.
- Most recent: Barber Daniel (President and CEO) — Open market sale of 25,000 shares on 2026-10-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)167,007 sh(9 txns)
Net Shares-167,007
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Barber Daniel | President and CEO | Open market sale | 2026-10-15 | 25,000 |
| Korczynski Sherry | Chief Commercial Officer | Option exercise | 2026-09-09 | 8,750 |
| Boyd Peter E. | Chief People Officer | In-the-money option exercise | 2026-09-09 | 2,293 |
| Jung Cassie | Chief Operating Officer | In-the-money option exercise | 2026-09-03 | 4,587 |
| Krop Julie | Reporting person | Option exercise | 2026-06-23 | 25,000 |
| Zalewski Thomas A. | Chief Legal Officer | Grant / award | 2026-05-18 | 100,000 |
| Cioffi Melina | SVP, Regulatory Affairs | Tax withholding | 2026-05-15 | 1,667 |
| BRAENDER LORI J | Corporate Secretary | Tax withholding | 2026-05-07 | 135,690 |
| TOTH A ERNEST JR | Chief Financial Officer | Tax withholding | 2026-05-05 | 92,652 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-10-15 | Barber Daniel | President and CEO | Open market sale | 25,000 | $4.22 |
| 2026-09-15 | Barber Daniel | President and CEO | Open market sale | 25,000 | $4.82 |
| 2026-09-09 | Korczynski Sherry | Chief Commercial Officer | Option exercise | 8,750 | $2.65 |
| 2026-09-09 | Korczynski Sherry | Chief Commercial Officer | Open market sale | 8,750 | $5.22 |
| 2026-09-09 | Boyd Peter E. | Chief People Officer | In-the-money option exercise | 2,293 | $0.96 |
| 2026-09-08 | Barber Daniel | President and CEO | In-the-money option exercise | 91,743 | $0.96 |
| 2026-09-03 | Jung Cassie | Chief Operating Officer | In-the-money option exercise | 4,587 | $0.96 |
| 2026-08-17 | Barber Daniel | President and CEO | Open market sale | 25,000 | $4.29 |
| 2026-08-14 | Korczynski Sherry | Chief Commercial Officer | Tax withholding | 2,714 | $4.25 |
| 2026-07-16 | Barber Daniel | President and CEO | Open market sale | 20,369 | $4.00 |
| 2026-07-15 | Barber Daniel | President and CEO | Open market sale | 4,631 | $4.03 |
| 2026-06-23 | Krop Julie | Reporting person | Option exercise | 25,000 | $0.71 |
| 2026-06-23 | Krop Julie | Reporting person | Open market sale | 25,000 | $5.02 |
| 2026-06-15 | Barber Daniel | President and CEO | Open market sale | 25,000 | $4.16 |
| 2026-06-08 | Korczynski Sherry | Chief Commercial Officer | Tax withholding | 2,714 | $0.00 |
| 2026-05-18 | Zalewski Thomas A. | Chief Legal Officer | Grant / award | 100,000 | $0.00 |
| 2026-05-15 | Barber Daniel | President and CEO | Open market sale | 8,257 | $4.29 |
| 2026-05-15 | Cioffi Melina | SVP, Regulatory Affairs | Tax withholding | 1,667 | $4.17 |
| 2026-05-07 | BRAENDER LORI J | Corporate Secretary | Tax withholding | 135,690 | $4.23 |
| 2026-05-05 | Boyd Peter E. | Chief People Officer | Tax withholding | 56,778 | $4.18 |
| 2026-05-05 | Barber Daniel | President and CEO | Tax withholding | 335,922 | $4.18 |
| 2026-05-05 | TOTH A ERNEST JR | Chief Financial Officer | Tax withholding | 92,652 | $4.18 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 00:40 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-19 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-16 | 4 | 2026-10-15 | View on SEC.gov → |
| 2026-10-15 | 8-K | 2026-10-15 | View on SEC.gov → |
| 2026-10-14 | 8-K | 2026-10-13 | View on SEC.gov → |
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-25 | 8-K | 2026-09-23 | View on SEC.gov → |
| 2026-09-17 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-09-16 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-10 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-09 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-03 | View on SEC.gov → |
Recent news
Headlines about AQST (Aquestive Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Board nomination rule changes took effect October 15 at Aquestive Therapeutics (AQST).
Stock Titan · 2026-10-19 -
AQST News | AQUESTIVE THERAPEUTICS INC (NASDAQ:AQST)
ChartMill · 2026-10-17 -
Richard J. Daly Submits Initial SEC Ownership Filing for Aquestive Therapeutics
Kalkine Media · 2026-10-16 -
Aquestive Therapeutics CEO sells $105,600 in shares
Investing.com · 2026-10-16 -
CEO sells 25,000 shares under a trading plan at Aquestive (AQST).
Stock Titan · 2026-10-16 -
Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade (NASDAQ:AQST)
Seeking Alpha · 2026-10-16 -
Richard J. Daly reports no directly held common shares in Aquestive Therapeutics (AQST).
Stock Titan · 2026-10-16 -
Aquestive: FDA Acceptance Of Anaphylm Resubmission Makes For Rating Upgrade
SeekingAlpha · 2026-10-16
No headlines in this category right now — try “All”.